SORS: Searching for Modulators of Cancer Therapeutic Resistance

Date: 27/Jun/2018 Time: 11:00

Place:

E106, C6 Building

Primary tabs

15th December 2022. 10:30 am. UPC's Vèrtex Building Auditorium + Gardens & Virtual

We are looking forward to celebrating the BSC staff annual meeting this year.

As in the previous edition, the event will be online and shorter.

The event will begin on December 15th at 10:30 am. We will send you a link nearer the time so you can connect.

Even more than normal, we hope that as many BSC staff as possible will be able to attend and participate.

You can participate by telling us:

What you would like to know about?

Let us know which subjects you find interesting to be incorporated into the BSC directors’ presentations.
Deadline exceeded

What would you like to listen to?

What you would like to share?

We would like to know more about your work, so we have booked one hour of the Annual Meeting to listen to 6 BSC employees that will explain what they do. We encourage you to be one of them.

What I would like to explain

Coming soon

 BSC Talks

We have booked time for 6 employees to explain in 6 minutes what you do at BSC.

The event will be VIRTUAL but the BSC Talks will be presented from the studio where the event is taking place.
 

We would like you to make short, attractive presentations (6 minutes) so all the BSC staff know what you do.

You could be one of those to go up the stage, and we will help you to prepare it.

What will you need to do?

  1. Let us know about what you would like to explain.
    • Send us a short video (landscape) of 45 seconds’ maximum explaining what you would like to present at annualmeeting2021@bsc.es
    • State your name, department, research group and a provisional title for your talk.
    • Deadline: November 29th.
  2. All the BSC staff will vote for the 6 most interesting proposals.
    • All videos will be available at the web page and the voting process will be open. Each employee will be able to vote up to 3 proposals.
  3. If your proposal is one of the chosen ones:
    • A training session will be organized for the 6 most voted.
  4. Prepare a 6 minutes’ presentation.
  5. The best presentation of December 15th will be awarded!

Directors’ presentation of 2022

We would like to know what subjects you are interested in so as to incorporate them in the directors’ presentation of the center. Fill in this form with your questions.

Objectives

To see the presentation please click here

Abstract

In the past recent years, there has been a substantial progress in the development of precise therapies against cancer. However, inference of the likelihood of cancer progression and/or therapeutic response based on data of a given cancer driver and/or therapeutic target is frequently incomplete. Too often cancer patients show insufficient benefit from an indicated therapy and this is in part likely due to incomplete knowledge of the molecular modifiers of current therapeutic approaches. Here, we have developed and applied an analytical framework to systematically identify the modulators of cancer drivers compiled through 15 human cancer types. More than 30,000 gene pairs have been identified, and the predictions are robust when effects are assessed using protein expression or somatic mutation data. The modulators are classified in different biological processes and signaling pathways according to the type of gene expression association with the corresponding drivers and to the effect on risk (increasing or decreasing) of relapse. While some modulators represent synthetic lethal interactions with their corresponding drivers, integration of drug and small compounds information reveals approximately 1,900 instances where cancer relapse could be modified. Experimental validations are ongoing. A data web portal will be open to the community to facilitate the discovery of new single or combined therapeutic approaches for improving cancer cure.

 

Short bio

Dr. Miquel Angel Pujana leads the “Resistance, Susceptibility and Tumor Progression” research group of the Catalan Institute of Oncology (ICO), IDIBELL (L’Hospitalet del Llobregat). The group generates and integrates experimental and bioinformatic data towards a better understanding on how cancer develops, progresses and responds to therapies. The team’s work is mainly focused on breast cancer, although novel approaches have been applied to different settings. In 2015, Dr. Pujana was designated Director of a new ICO research program focused on “therapeutic resistance”; ProCURE. This program includes 10 independent research groups across three institutes and whose activity is centered on “fighting” cancer therapeutic resistance. Dr. Pujana is author of >100 peer-review publications, including studies of new cancer susceptibility genes, genetic interactions influencing risk, molecular mechanisms of resistance, and integrative-network analysis of biological and/or medical data. Dr. Pujana is also member of the Consortium of the Investigators of Modifiers of BRCA1/2 (CIMBA) and in this context leads studies on the genetic basis of breast cancer risk.

 

 

Speakers

Dr. Miquel Angel Pujana leads the “Resistance, Susceptibility and Tumor Progression” research group of the Catalan Institute of Oncology (ICO), IDIBELL (L’Hospitalet del Llobregat). The group generates and integrates experimental and bioinformatic data towards a better understanding on how cancer develops, progresses and responds to therapies. The team’s work is mainly focused on breast cancer, although novel approaches have been applied to different settings. In 2015, Dr. Pujana was designated Director of a new ICO research program focused on “therapeutic resistance”; ProCURE. This program includes 10 independent research groups across three institutes and whose activity is centered on “fighting” cancer therapeutic resistance. Dr. Pujana is author of >100 peer-review publications, including studies of new cancer susceptibility genes, genetic interactions influencing risk, molecular mechanisms of resistance, and integrative-network analysis of biological and/or medical data. Dr. Pujana is also member of the Consortium of the Investigators of Modifiers of BRCA1/2 (CIMBA) and in this context leads studies on the genetic basis of breast cancer risk.